Cell-penetrating peptide-based nanovehicles potentiate lymph metastasis targeting and deep penetration for anti-metastasis therapy

Abstract

Lymph metastasis is a vital pathway of cancer cell dissemination, and insidious lymph node metastasis increases the risk of distant cancer metastasis. Current therapies for lymph metastasis are largely restricted by limited targeting and penetration capacity. Herein, we report that an r9 cell-penetrating peptide-based cabazitaxel nanovehicle (r9-CN) displays prominent lymph metastasis targeting and deep penetration ability after intravenous injection for effective anti-metastasis therapy.Methods: The r9-CN and CN nanovehicles were prepared by thin film dispersion, using DSPE-PEG2000 as the nano-carrier material and cabazitaxel as the model drug to fabricate r9-modified nano-micelles by self-assembly. The morphology, size, and stability in physiological solutions of r9-CN and CN were characterized. The targeting, biodistribution, deep penetration, and therapeutic efficacy of r9-CN and CN were systematically explored in vitro and in vivo.Results: The r9-CN nanovehicle consists of homogeneous particles with a mean diameter of 13 nm and zeta potential of +0.75 mV. Compared with the nanovehicle lacking the r9 peptide (CN), r9-CN exhibits long retention and deep penetration in the tumor mass, and considerably enhances accumulation and flexible permeation in metastatic lymph nodes, thereby notably suppressing primary tumor growth, lymph node metastasis, and distant lung metastasis.Conclusion: The cumulative findings reveal that r9-CN offers a promising delivery platform, enabling efficient lymph metastasis targeting and deep penetration for effective anti-metastasis therapy.

Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles

“…Therefore, D-bLP and DM-bLP displayed similar in vivo distribution profiles, which exhibited superior tumor accumulation and penetration capacity versus the counterpart D-Lipo. The opening in the tumor ECM is generally <40 nm, and increasing data have confirmed the efficient penetration capacity of smallsized nanoparticles in solid tumors 19,21,39,41,42 . The small particle size of D-bLP and DM-bLP (< 30 nm) may be a crucial contributor to the superior tumor-penetrating capacity.…”

Improvement of Cell Penetrating Peptide for Efficient siRNA Targeting of Tumor Xenografts in Zebrafish Embryos

“…Promising results have been obtained with different CPPs in biological response on cell lines and in vivo studies . However, CPPs are usually non‐selective, which may lead to great losses in the circulation, and only a small percentage can accumulate within target cells.…”

Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application

“…R9-CN clearly suppressed 1.4-fold of tumor growth rate and showed a 63.3% inhibition rate of lung metastasis than CN in a breast cancer lymphatic metastasis model. CPPs modified nanoparticles were an effective anti-metastasis platform with deep lymph penetration (Hu et al, 2018).…”